drugset / Trial / NCT05309200

A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

NCT05309200 ↗

Phase 2 Completed 47 enrolled Ocelot Bio, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites. The study aims are to evaluate the safety and efficacy of OCE-205 at various doses. Participants will receive treatment by intravenous infusion. Participants will continue with this treatment until participants meets primary endpoint or any discontinuation criteria.

Timeline

Start
2022-04-28
Primary completion
2023-09-12
Completion
2023-10-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject INVOPRESSIN Protein / enzyme biologic 8 ug Intravenous
Subject INVOPRESSIN Protein / enzyme biologic 15 ug Intravenous
Subject INVOPRESSIN Protein / enzyme biologic 30 ug Intravenous
Subject INVOPRESSIN Protein / enzyme biologic 50 ug Intravenous